Zoetis (ZTS) Other Non-Current Assets (2012 - 2026)
Zoetis (ZTS) posted quarterly Other Non-Current Assets of $351.0 million for Q1 2026, up 51.29% year-over-year from $232.0 million in Q1 2025, and up 7.34% quarter-over-quarter from $327.0 million in Q4 2025.
Zoetis (ZTS) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Other Non-Current Assets for 15 consecutive years, with $351.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 51.29% year-over-year to $351.0 million; the TTM figure through Mar 2026 stood at $351.0 million (up 51.29% YoY), while the FY2025 annual figure was $327.0 million, up 30.8% from the prior year.
- Other Non-Current Assets grew to $351.0 million in Q1 2026 per ZTS's latest filing, from $327.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $351.0 million in Q1 2026 and bottomed at $129.0 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $224.1 million across 5 years, with a median of $216.0 million in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 88.44% — and 2025, when it slipped 18.1%.
- Zoetis' Other Non-Current Assets stood at $147.0 million in 2022, then jumped by 40.14% to $206.0 million in 2023, then climbed by 21.36% to $250.0 million in 2024, then soared by 30.8% to $327.0 million in 2025, then increased by 7.34% to $351.0 million in 2026.
- Business Quant data shows ZTS's Other Non-Current Assets at $351.0 million in Q1 2026, $327.0 million in Q4 2025, and $293.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 384.00 Mn |
| Mar 31, 2026 | 351.00 Mn |
| Dec 31, 2025 | 327.00 Mn |
| Sep 30, 2025 | 293.00 Mn |
| Jun 30, 2025 | 267.00 Mn |
| Mar 31, 2025 | 232.00 Mn |
| Dec 31, 2024 | 250.00 Mn |
| Sep 30, 2024 | 215.00 Mn |
| Jun 30, 2024 | 326.00 Mn |
| Mar 31, 2024 | 227.00 Mn |
| Dec 31, 2023 | 206.00 Mn |
| Sep 30, 2023 | 216.00 Mn |
| Jun 30, 2023 | 173.00 Mn |
| Mar 31, 2023 | 143.00 Mn |
| Dec 31, 2022 | 147.00 Mn |
| Sep 30, 2022 | 161.00 Mn |
| Jun 30, 2022 | 147.00 Mn |
| Mar 31, 2022 | 129.00 Mn |
| Dec 31, 2021 | 111.00 Mn |
| Sep 30, 2021 | 112.00 Mn |